PharmaCyte Biotech, Inc. (NASDAQ:PMCB – Get Free Report) saw a significant decline in short interest in the month of November. As of November 15th, there was short interest totalling 51,900 shares, a decline of 15.9% from the October 31st total of 61,700 shares. Based on an average daily trading volume, of 34,700 shares, the days-to-cover ratio is presently 1.5 days. Currently, 0.7% of the company’s shares are sold short.
PharmaCyte Biotech Stock Up 0.0 %
PMCB stock opened at $1.71 on Monday. PharmaCyte Biotech has a twelve month low of $1.39 and a twelve month high of $2.58. The stock has a market capitalization of $13.13 million, a price-to-earnings ratio of 2.59 and a beta of -0.20. The firm’s fifty day simple moving average is $1.77 and its two-hundred day simple moving average is $1.88.
PharmaCyte Biotech (NASDAQ:PMCB – Get Free Report) last issued its quarterly earnings results on Monday, September 16th. The company reported $0.14 EPS for the quarter.
PharmaCyte Biotech Company Profile
PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer.
Featured Stories
- Five stocks we like better than PharmaCyte Biotech
- The Risks of Owning Bonds
- Analog Devices: Why the Uptrend Could Accelerate in 2025
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Texas Pacific Land: Permian Basin Powerhouse With an AI Edge
- What is the Nikkei 225 index?
- ServiceNow: Will the High-Flyer Finally Split in 2024?
Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
